ASCO 2019: Amgen adds BiTE to KRAS data

5 June 2019

The headline-grabbing results on AMG 510, the first KRASG12C inhibitor to reach the clinical stage, were not the only data to be shared by US biotech Amgen (Nasdaq: AMGN) on its early-stage oncology pipeline.

New data from Phase I studies evaluating investigational bispecific T cell engager (BiTE) molecules have also been presented, including AMG 420 safety and efficacy results in patients with relapsed and/or refractory multiple myeloma (R/R MM).

BiTE technology is a targeted immuno-oncology (I-O) platform that is designed to engage patients' own T cells to a tumor-specific antigen, activating the cytotoxic potential of T cells.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK